| Docetaxel and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Cancer |
|
Eun Hee Cho;Keun Hyok Cho;Young Bong Song;Ik Sung Choi;Jae Won Choi;Seung Hyun Nam;Bong Seog Kim |
| 국소 진행성 두경부암 환자에서의 Docetaxel과 Cisplatin 유도화학요법 |
|
조은희;조근혁;송영봉;최익성;최재원;남승현;김봉석 |
|
|
|
|
| Abstract |
Objectives: To evaluate the efficacy and safety of induction chemotherapy with docetaxel and cisplatin in locally advanced head and neck cancer.
Materials and Methods: Between June 1998 and December 2004, 30 patients were enrolled and among them, 20 patients were evaluable. Patients were treated with docetaxel 75mg/m² and cisplatin 60mg/m² on day 1 every 21 days.
Results
The median age was 71(range 54-80) years old. All 20 patients were male. Nineteen patients had pathologically squamous cell carcinoma and 1 had undifferentiated carcinoma. Fourteen of 20 patients(70%) demonstrated an objective response with two(10%) achieving a complete clinical response and eleven(60%) a partial response. The median response duration was 5.3(1.6-32.1) months and the median time to progression was 5.6(1.4-33.8) months. The median overall survival of all patients was 14(range 2.2-34) months. The median overall survival of responders was 17.5(range 5-34) months and that of non-responders was 3.2(range 2.2-23) months, but it was not statistically significant(p=0.106). During a total of 92 cycles, granulocytopenia worse than CTC(Common toxicity criteria) grade 2 occurred in 6%, thrombocytopenia in 2%, and anemia in 3%, respectively. Non-hematologic toxicities were minor and easily controlled.
Conclusion
The induction chemotherapy of docetaxel and cisplatin has moderate efficacy with acceptable toxicities in patients with locally advanced head and neck cancer. |
| Key Words:
Head and neck cancer, Docetaxel, Cisplatin |
|
PDF Links
Full text via DOI
Download Citation
